StockData

Integra LifeSciences vs ICU Medical

IART and ICUI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IART and ICUI compare

ICU Medical is the larger company, worth 4.2 times as much as Integra LifeSciences ($4.4B against $1.1B).

On earnings, Integra LifeSciences is cheaper: it trades at 79.7× trailing earnings, against 147× for ICU Medical.

Integra LifeSciences grew revenue faster over the last twelve months (0.84% versus −9.0% for ICU Medical).

ICU Medical keeps more of each dollar of sales as profit, with a net margin of 1.4% compared with 0.79% at Integra LifeSciences.

Integra LifeSciences scores higher on the StockData Score (9 against 7 for ICU Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIARTICUI
Size and price
Market cap$1.1B$4.4B
Share price$13.55$176.91
Change, 1 year15.3%29.6%
Change, 5 years−79.1%−24.0%
Beta (5Y)1.911.13
Employees3,70013K
StockData Score
Total score9 (better)7
Valuation score3 (better)1
Growth score22
Performance score33
Health score11
Dividend score00
Valuation
P/E79.7× (better)147×
P/S0.6× (better)2.0×
P/B1.0× (better)2.1×
EV/EBITDA10.2× (better)19.6×
P/FCF12.3× (better)28.9×
FCF yield8.1% (better)3.5%
Fair value$14.78$95.24
Margin of safety8.3% (better)−85.7%
Growth
Revenue growth (TTM)0.84% (better)−9.0%
Revenue growth, 5Y average3.6%11.9% (better)
EPS growth, 5Y average–−62.5%
Profitability
Gross margin52.4% (better)39.1%
Operating margin4.4% (better)3.3%
Net margin0.79%1.4% (better)
FCF margin5.2%7.1% (better)
Return on equity1.2%1.4% (better)
Return on invested capital5.6% (better)2.3%
Financial health
Debt / equity–0.57
Net debt / EBITDA–3.41
Interest coverage0.8×0.9× (better)
Current ratio3.62 (better)2.43
Altman Z-score1.272.54 (better)
Piotroski F-score56 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions94.4%104%
Held by insiders3.4%1.8%
Insider net buying, 12 months$0 (better)−$7.8M
Short interest, % of float10.5%6.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.